CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common ...

Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][3] - The company's lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments, including several DNA Damage Response (DDR) pathways [3] Upcoming Events - Daniel Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference 2025 on May 8, 2025, at 12:30 PM ET [1][2] - The presentation will be accessible via a webcast on the Actuate website, and the management team will participate in one-on-one investor meetings during the event [2]